Karin Reif

Karin Reif has a diverse and extensive work experience in the field of biotechnology and pharmaceutical research. Karin is currently working as the Director at TRexBio since April 2022. Prior to that, Karin was the Owner and Principal Consultant at KARBio LLC, starting in July 2015.

Before transitioning into consulting, Karin spent a significant part of their career at Genentech, Inc. where they held various leadership roles. Karin started at Genentech in 2003 and worked as a Scientist and Research Project Team Leader. In this role, they led discovery research laboratory, cross-functional teams, and business collaborations. Karin was responsible for the discovery and integrated development of novel therapeutic targets. Karin also provided scientific, strategic, and technical direction to pre-clinical and clinical drug development teams, including advising on biomarker development, pharmacokinetic/pharmacodynamic (PK/PD) response evaluation, safety assessment, diagnostic strategy, and indication selection. Karin authored INDs and Investigator's Brochures, and had direct interactions with the FDA.

At Genentech, Karin also held positions as the Biology Team Leader of small molecule programs targeting rheumatoid arthritis and lupus, and as the Research Project Team Leader of biologic programs for asthma and allergic diseases. In these roles, they validated targets, initiated programs, advanced numerous clinical candidates into early development, identified novel pharmacodynamic assays and biomarkers, and determined mechanisms of toxicity and the roles of kinases in various biology and autoimmune indications. Karin also established collaborations with academia to identify additional indications.

Before joining Genentech, Karin worked as a Postdoctoral Fellow at the University of California San Francisco, Howard Hughes Medical Institute from 1997 to 2003. In this role, they focused on determining the mechanisms of lymphocyte migration and B cell chemotaxis in response to antigen. Prior to their postdoctoral fellowship, Karin worked as a Graduate Researcher at Imperial Cancer Research Fund from 1993 to 1997.

Overall, Karin Reif has demonstrated expertise in scientific research, team leadership, drug development, and strategic decision-making in the biotechnology and pharmaceutical industry.

Karin Reif completed their education in the field of Biochemistry, Immunology, and Biophysics. Karin obtained a Diploma (M.Sc.) from Freie Universität Berlin in 1992 and later pursued a Doctor of Philosophy (Ph.D.) degree from UCL, specializing in Biochemistry and Immunology.